



Mouse Anti-Nivolumab monoclonal antibody, clone 7H6 (CABT-ZB213)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

Product Overview	CABT-ZB213 is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Nivolumab.
Specificity	The product is specific for Nivolumab.
Target	Nivolumab
Immunogen	Nivolumab
Isotype	IgG1
Source/Host	Mouse
Clone	7H6
Purification	Protein A purified
Conjugate	Unconjugated
Applications	<p>ELISA(det), PK study</p> <p>Recommended Working Concentration:</p> <p>0.01-0.1 µg/ml</p> <p>We recommend the following for sandwich ELISA (Capture - Detection):</p> <p>CABT-ZB212 - CABT-ZB213; CABT-ZB212 - CABT-ZB214</p> <p>The antibody is recommended as a detection antibody in a pharmacokinetic (PK) bridging assay with capture antibody CABT-ZB212.</p>
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/mL.
Format	Purified, Lyophilized.

Size	40 µg
Buffer	Lyophilized with PBS, pH 7.4, contains 0.02% sodium azide.
Preservative	0.02% sodium azide
Storage	The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid freeze/thaw cycles.
Ship	Wet ice

BACKGROUND

Introduction	Nivolumab (Opdivo) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Nivolumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.
Keywords	Mouse monoclonal antibody to Opdivo; MDX-1106; Nivolumab

GENE INFORMATION

Synonyms	Mouse monoclonal antibody to Opdivo; MDX-1106; Nivolumab
-----------------	--